• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.

作者信息

Zanen A L, Adriaansen H J, van Bommel E F, Posthuma R, Th de Jong G M

机构信息

Department of Internal Medicine, Drechtsteden Hospital, Dordrecht, The Netherlands.

出版信息

Nephrol Dial Transplant. 1996 May;11(5):820-4. doi: 10.1093/oxfordjournals.ndt.a027405.

DOI:10.1093/oxfordjournals.ndt.a027405
PMID:8671901
Abstract

BACKGROUND

Chronic haemodialysis causes blood loss and iron-deficiency. This can be corrected with intravenous preparations, e.g. sodium ferric-gluconate (FeGl). In two patents complaints of hypotension and malaise during FeGl infusion coincided with high levels of serum iron and a calculated transferrin iron saturation above 100%. Iron toxicity could be the cause of these complaints. Free iron is known to aggravate the toxicity of free radicals and other reactive oxygen products that are constantly formed in the body. We compared four rates of FeGl infusion with regard to iron parameters.

METHODS

20 dialysis patients received a total of 26 infusions of FeGl. A rapid infusion of 135 mg (Protocol A (n=10)) or 62.5 mg (Protocol B (n=7)) of FeGl was given during the last 30 min of dialysis. A slow infusion of 125 mg (Protocol C (n=9)) or 62.5 mg (Protocol D (n=10)) was given during 4 or 4.5 h of dialysis. Blood was taken at regular intervals, before, during, and after dialysis for determination of serum iron, transferrin, ferritin, haematocrit, total protein, albumin, and lactate dehydrogenase (LDH). Transferrin saturation was calculated from transferrin and serum iron.

RESULTS

With rapid infusion A (125 mg) the highest levels of serum iron (median 120 (range 40-159) micromol/l) and transferrin saturation (207 (84-331)%) were seen at the end of the infusion. These were significantly higher than the peak levels with B, C, and D (P</=0.03). With rapid infusion B (62.5 mg), peak levels were intermediately high (serum iron 61 (50-96) micromol/l; transferrin saturation 118 (91-174)%). With slow infusion C (125 mg) similar peak levels were seen (serum iron 83 (43-106) micromol/l; transferrin saturation 141 (88-172)%). With slow infusion D (62.5 mg), the lowest peak levels were seen (serum iron 38 (31-55) micromol/l; transferrin saturation 78 (43-92)%). These levels were significantly lower than those with A, B and C (P<=0.002). Only with D all patients showed a transferrin saturation lower than 100%. Ferritin was increased before the next dialysis in all patients. LDH was not significantly elevated during any infusion.

CONCLUSIONS

The commonly used rapid infusion rate (A) of FeGl causes 'oversaturation' of transferrin. This is compatible with iron toxicity due to free iron which may explain our patients' complaints. Free iron cannot be measured directly. LDH as a crude measure of cell damage was not elevated. Better measurements to prove free iron toxicity, like lipid peroxides, are not yet readily available. Infusion during a longer period at a lower dose (D) is effective and eliminates 'Oversaturation' of transferrin and probably the danger of iron toxicity.

摘要

相似文献

1
'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.
Nephrol Dial Transplant. 1996 May;11(5):820-4. doi: 10.1093/oxfordjournals.ndt.a027405.
2
Safety of intravenous injection of iron saccharate in haemodialysis patients.血液透析患者静脉注射蔗糖铁的安全性。
Nephrol Dial Transplant. 1996 Sep;11(9):1797-802.
3
Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.静脉注射蔗糖铁后血液透析患者血浆中的非转铁蛋白结合铁
Eur J Clin Invest. 2002 Mar;32 Suppl 1:36-41. doi: 10.1046/j.1365-2362.2002.0320s1036.x.
4
Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.血液透析患者静脉注射右旋糖酐铁、葡萄糖酸铁钠和蔗糖铁后氧化应激标志物的比较。
Pharmacotherapy. 2007 Mar;27(3):343-50. doi: 10.1592/phco.27.3.343.
5
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.葡萄糖酸铁对血清铁蛋白高且转铁蛋白饱和度低的贫血血液透析患者疗效显著:铁蛋白升高时静脉注射铁剂的透析患者反应(DRIVE)研究结果
J Am Soc Nephrol. 2007 Mar;18(3):975-84. doi: 10.1681/ASN.2006091034. Epub 2007 Jan 31.
6
Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.低剂量持续铁剂治疗可使慢性血液透析患者实现正铁平衡并降低血清转铁蛋白水平。
Nephrol Dial Transplant. 2004 Jun;19(6):1564-70. doi: 10.1093/ndt/gfh136. Epub 2004 Mar 5.
7
Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.静脉注射蔗糖铁后血液透析患者血清中具有催化活性的铁与细菌生长
Nephrol Dial Transplant. 2000 Nov;15(11):1827-34. doi: 10.1093/ndt/15.11.1827.
8
A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.一项关于蔗糖铁(Venofer)与葡萄糖酸铁(Ferrlecit)对接受重组人促红细胞生成素治疗的血液透析患者疗效和安全性的随机对照平行组试验。
Nephrol Dial Transplant. 2001 Jun;16(6):1239-44. doi: 10.1093/ndt/16.6.1239.
9
Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients.每周大剂量静脉注射葡萄糖酸铁钠对腹膜透析患者是安全有效的。
Nephrol Nurs J. 2002 Apr;29(2):183-6.
10
Iron supplementation in haemodialysis--practical clinical guidelines.血液透析中的铁补充——实用临床指南
Nephrol Dial Transplant. 1998 Oct;13(10):2572-7. doi: 10.1093/ndt/13.10.2572.

引用本文的文献

1
Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study.生物分子冠能否引发过敏反应?——一项概念验证研究。
Biointerphases. 2021 Feb 3;16(1):011008. doi: 10.1116/6.0000755.
2
Intravenous iron delivers a sustained (8-week) lowering of pulmonary artery pressure during exercise in healthy older humans.静脉注射铁剂可使健康老年人在运动期间的肺动脉压持续(8周)降低。
Physiol Rep. 2019 Aug;7(13):e14164. doi: 10.14814/phy2.14164.
3
Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.
口服水合柠檬酸铁比静脉注射含糖氧化铁引起的氧化应激更少。
Kidney Int Rep. 2017 Nov 3;3(2):364-373. doi: 10.1016/j.ekir.2017.10.016. eCollection 2018 Mar.
4
Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.接受静脉注射羧麦芽糖铁的非透析慢性肾脏病患者的肾功能:随机FIND-CKD试验分析
BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6.
5
Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.用于儿童和青年成人磁共振成像的菲立磁安全性报告。
Invest Radiol. 2016 Apr;51(4):221-227. doi: 10.1097/RLI.0000000000000230.
6
Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.血液透析患者静脉补铁治疗实践与心血管事件短期风险
PLoS One. 2013 Nov 1;8(11):e78930. doi: 10.1371/journal.pone.0078930. eCollection 2013.
7
Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.不同蔗糖铁类似静脉制剂在大鼠模型中诱导的氧化应激和炎症比较
Inflamm Allergy Drug Targets. 2012 Feb;11(1):66-78. doi: 10.2174/187152812798889358.
8
Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.铁过载:在 CKD 贫血纠正的随机试验中导致不良结局的一个因素。
Int Urol Nephrol. 2012 Apr;44(2):499-507. doi: 10.1007/s11255-011-0028-5. Epub 2011 Jul 10.
9
Cardiorenal syndromes.心肾综合征
World J Cardiol. 2011 Jan 26;3(1):1-9. doi: 10.4330/wjc.v3.i1.1.
10
Constant voltage 'Iron'tophoresis.恒压电渗疗法。
Pharm Dev Technol. 2011 Oct;16(5):483-8. doi: 10.3109/10837450.2010.492219. Epub 2010 Jun 14.